This immune response leads to inflammation and damage to the myelin sheath. As a result, nerve signals are disrupted, leading to weakness, numbness, and paralysis. There are several subtypes of Guillain-Barre Syndrome, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which is the most common type, as well as acute motor axonal neuropathy (AMAN) and Miller Fisher syndrome.
Most people with Guillain-Barre Syndrome experience a gradual recovery over weeks or months, although some individuals may have lingering weakness or other long-term effects. Rehabilitation is often necessary to help patients regain their strength and functionality.
Epidemiology
The annual incidence of GBS is estimated to be around 0.6 to 4 cases per 100,000 individuals. Incidence rates may vary across different populations and geographic regions. GBS can affect individuals of all ages, but it is more common in adults and older individuals. The peak age of onset is between 30 and 50 years old. Additionally, GBS appears to affect males slightly more often than females. In some regions, GBS has been observed to have seasonal patterns, with higher incidence rates reported during certain times of the year.
The reason for this seasonal variation is not entirely understood but could be linked to the prevalence of infections that trigger the condition. Occasionally, outbreaks of GBS have been reported in certain regions or after specific infections, such as the Zika virus outbreak in 2015-2016, which was associated with an increase in GBS cases in affected areas.
A small but increased risk of GBS is associated with some influenza vaccines, particularly the 1976 swine flu vaccine. However, the overall risk is extremely low, and the benefits of vaccination in preventing influenza far outweigh this risk. The incidence of GBS can vary between countries and regions. Some studies have suggested that it might be more common in developed countries compared to developing countries, but differences may also influence this observation in healthcare access and reporting systems.
Anatomy
Pathophysiology
GBS is often triggered by preceding infections, typically bacterial or viral. Molecular mimicry is one of the proposed mechanisms for GBS development. Infections, particularly those caused by Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and Zika virus, can produce antigens that closely resemble the structure of the peripheral nerves’ myelin sheath or nerve fibers. While trying to fight the infection, the immune system can mistakenly attack these similar antigens on the nerves, leading to an autoimmune response.
The immune system, primarily involving T-cells and B-cells, becomes activated and attacks the peripheral nerves. This immune response leads to inflammation and damage to the myelin sheath—the protective covering of the nerves—and sometimes to the axons (nerve fibers). As the myelin sheath is damaged, nerve conduction is disrupted, resulting in the characteristic symptoms of GBS, such as weakness, numbness, and paralysis.
The blood-nerve barrier is a protective barrier that separates the blood vessels from the peripheral nerves. In GBS, the immune response can cause the breakdown of this barrier, leading to an influx of immune cells and proteins into the nerve tissues. This further promotes inflammation and nerve damage. The autoimmune response and activation of the immune system lead to inflammation in and around the affected nerves.
Inflammatory cells, cytokines, and other immune mediators contribute to tissue damage and edema, further impairing nerve function. In some cases, the immune response can directly damage the axons of the nerves. This type of nerve damage can lead to more severe and prolonged weakness and slower recovery compared to cases with primary demyelination.
Etiology
Guillain-Barre Syndrome (GBS) is an autoimmune disorder whose etiology involves a complex interplay of factors. The primary trigger for GBS is often a preceding infection, most commonly caused by bacteria or viruses. Infections such as Campylobacter jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Zika virus have been implicated as potential triggers for GBS. During these infections, the immune system responds to combat the invading pathogens.
However, in some individuals, the immune system’s response becomes misdirected, leading to an attack on the body’s peripheral nerves. Infections can produce antigens that closely resemble components of the myelin sheath or nerve fibers of peripheral nerves. These similar antigens can confuse the immune system, leading it to attack the infection and the nerve tissues, resulting in an autoimmune response.
While the etiology of GBS is not entirely understood, ongoing research continues to shed light on the underlying mechanisms and contributing factors. Understanding the complex interactions between infections, the immune system, and peripheral nerves is crucial for developing more effective treatments and interventions for this rare and potentially severe neurological disorder.
Genetics
Prognostic Factors
Following the acute phase of Guillain-Barre Syndrome (GBS), most patients experience favorable outcomes, with over 80% achieving independent ambulation within six months.
The mortality rate during the acute stage of the illness remains below 5%. However, a smaller subset, accounting for less than 20% of cases, may still face substantial disabilities despite receiving the standard of care for GBS.
Clinical History
Clinical History
Before the onset of GBS symptoms, there is often a prodromal phase characterized by a recent history of infection or illness. Commonly, GBS is triggered by bacterial or viral infections, such as respiratory or gastrointestinal infections, including Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and others. The prodromal phase can last for a few days to a few weeks.
The hallmark symptoms of GBS usually start with weakness and tingling sensations in the extremities, most commonly in the feet and hands. These symptoms typically progress rapidly and symmetrically, spreading to the arms and legs. The onset of symptoms is usually sudden and may occur within a few hours to a few days after the prodromal phase.
After the initial progression of symptoms, there is a plateau phase where the weakness and sensory deficits stabilize and reach their maximum severity. This phase can last for several days to a few weeks. During this period, patients may experience significant muscle weakness and difficulty walking and may even have difficulty performing basic activities of daily living.
Physical Examination
Physical ExaminationÂ
One of the primary features of GBS is symmetrical muscle weakness, which typically starts in the extremities and progresses upwards. The weakness may be more pronounced in the legs than in the arms. Patients may have difficulty lifting their arms or legs against gravity, and their muscle strength may be significantly reduced. Deep tendon reflexes, such as the knee jerk reflex (patellar reflex) or ankle reflex (Achilles reflex), are low during the examination.
In GBS, these reflexes are often diminished or absent due to nerve damage affecting the communication between the muscles and the spinal cord. GBS can cause sensory disturbances, such as numbness, tingling, reduced sensitivity to touch, temperature, and pain. These sensory abnormalities are often symmetrical and may follow the same distribution as muscle weakness.Â
In some cases of GBS, cranial nerves can be affected, leading to various cranial nerve deficits. For example, patients may experience facial weakness or paralysis (facial nerve palsy), difficulty swallowing or speaking, diplopia, or other cranial nerve-related symptoms. GBS can also impact the autonomic nervous system, leading to autonomic dysfunction.
This may manifest as changes in blood pressure, heart rate, sweating, and other involuntary bodily functions. The weakness and paralysis in GBS typically follow a symmetrical pattern, affecting both sides of the body similarly. Over time, as the nerves are affected, muscle wasting or atrophy may be observed in the affected limbs.Â
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Differential DiagnosesÂ
Acute Intermittent Porphyria
Tick Paralysis
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Currently, two standard treatment options are considered for Guillain-Barre Syndrome (GBS): intravenous immunoglobulin (IVIG) and plasma exchange. Although the exact mechanism of IVIG’s immune-modulating action remains to be fully understood, both IVIG and plasma exchange have been shown to be equally effective in managing GBS.
Plasma exchange involves five sessions of exchanging a volume of plasma. Treatment with either IVIG or plasma exchange within four weeks of symptom onset has demonstrated positive effects, with stronger benefits seen when treatment is initiated within two weeks.
Interestingly, corticosteroids, such as oral prednisone and intravenous methylprednisolone, have not shown significant benefits compared to placebo or when combined with IVIG and plasma exchange. Despite this, the overall treatment has been found to shorten the recovery duration of GBS. In a study, treated patients achieved independent ambulation 32 days faster than untreated patients.
This immune response leads to inflammation and damage to the myelin sheath. As a result, nerve signals are disrupted, leading to weakness, numbness, and paralysis. There are several subtypes of Guillain-Barre Syndrome, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which is the most common type, as well as acute motor axonal neuropathy (AMAN) and Miller Fisher syndrome.
Most people with Guillain-Barre Syndrome experience a gradual recovery over weeks or months, although some individuals may have lingering weakness or other long-term effects. Rehabilitation is often necessary to help patients regain their strength and functionality.
The annual incidence of GBS is estimated to be around 0.6 to 4 cases per 100,000 individuals. Incidence rates may vary across different populations and geographic regions. GBS can affect individuals of all ages, but it is more common in adults and older individuals. The peak age of onset is between 30 and 50 years old. Additionally, GBS appears to affect males slightly more often than females. In some regions, GBS has been observed to have seasonal patterns, with higher incidence rates reported during certain times of the year.
The reason for this seasonal variation is not entirely understood but could be linked to the prevalence of infections that trigger the condition. Occasionally, outbreaks of GBS have been reported in certain regions or after specific infections, such as the Zika virus outbreak in 2015-2016, which was associated with an increase in GBS cases in affected areas.
A small but increased risk of GBS is associated with some influenza vaccines, particularly the 1976 swine flu vaccine. However, the overall risk is extremely low, and the benefits of vaccination in preventing influenza far outweigh this risk. The incidence of GBS can vary between countries and regions. Some studies have suggested that it might be more common in developed countries compared to developing countries, but differences may also influence this observation in healthcare access and reporting systems.
GBS is often triggered by preceding infections, typically bacterial or viral. Molecular mimicry is one of the proposed mechanisms for GBS development. Infections, particularly those caused by Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and Zika virus, can produce antigens that closely resemble the structure of the peripheral nerves’ myelin sheath or nerve fibers. While trying to fight the infection, the immune system can mistakenly attack these similar antigens on the nerves, leading to an autoimmune response.
The immune system, primarily involving T-cells and B-cells, becomes activated and attacks the peripheral nerves. This immune response leads to inflammation and damage to the myelin sheath—the protective covering of the nerves—and sometimes to the axons (nerve fibers). As the myelin sheath is damaged, nerve conduction is disrupted, resulting in the characteristic symptoms of GBS, such as weakness, numbness, and paralysis.
The blood-nerve barrier is a protective barrier that separates the blood vessels from the peripheral nerves. In GBS, the immune response can cause the breakdown of this barrier, leading to an influx of immune cells and proteins into the nerve tissues. This further promotes inflammation and nerve damage. The autoimmune response and activation of the immune system lead to inflammation in and around the affected nerves.
Inflammatory cells, cytokines, and other immune mediators contribute to tissue damage and edema, further impairing nerve function. In some cases, the immune response can directly damage the axons of the nerves. This type of nerve damage can lead to more severe and prolonged weakness and slower recovery compared to cases with primary demyelination.
Guillain-Barre Syndrome (GBS) is an autoimmune disorder whose etiology involves a complex interplay of factors. The primary trigger for GBS is often a preceding infection, most commonly caused by bacteria or viruses. Infections such as Campylobacter jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Zika virus have been implicated as potential triggers for GBS. During these infections, the immune system responds to combat the invading pathogens.
However, in some individuals, the immune system’s response becomes misdirected, leading to an attack on the body’s peripheral nerves. Infections can produce antigens that closely resemble components of the myelin sheath or nerve fibers of peripheral nerves. These similar antigens can confuse the immune system, leading it to attack the infection and the nerve tissues, resulting in an autoimmune response.
While the etiology of GBS is not entirely understood, ongoing research continues to shed light on the underlying mechanisms and contributing factors. Understanding the complex interactions between infections, the immune system, and peripheral nerves is crucial for developing more effective treatments and interventions for this rare and potentially severe neurological disorder.
Following the acute phase of Guillain-Barre Syndrome (GBS), most patients experience favorable outcomes, with over 80% achieving independent ambulation within six months.
The mortality rate during the acute stage of the illness remains below 5%. However, a smaller subset, accounting for less than 20% of cases, may still face substantial disabilities despite receiving the standard of care for GBS.
Clinical History
Before the onset of GBS symptoms, there is often a prodromal phase characterized by a recent history of infection or illness. Commonly, GBS is triggered by bacterial or viral infections, such as respiratory or gastrointestinal infections, including Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and others. The prodromal phase can last for a few days to a few weeks.
The hallmark symptoms of GBS usually start with weakness and tingling sensations in the extremities, most commonly in the feet and hands. These symptoms typically progress rapidly and symmetrically, spreading to the arms and legs. The onset of symptoms is usually sudden and may occur within a few hours to a few days after the prodromal phase.
After the initial progression of symptoms, there is a plateau phase where the weakness and sensory deficits stabilize and reach their maximum severity. This phase can last for several days to a few weeks. During this period, patients may experience significant muscle weakness and difficulty walking and may even have difficulty performing basic activities of daily living.
Physical ExaminationÂ
One of the primary features of GBS is symmetrical muscle weakness, which typically starts in the extremities and progresses upwards. The weakness may be more pronounced in the legs than in the arms. Patients may have difficulty lifting their arms or legs against gravity, and their muscle strength may be significantly reduced. Deep tendon reflexes, such as the knee jerk reflex (patellar reflex) or ankle reflex (Achilles reflex), are low during the examination.
In GBS, these reflexes are often diminished or absent due to nerve damage affecting the communication between the muscles and the spinal cord. GBS can cause sensory disturbances, such as numbness, tingling, reduced sensitivity to touch, temperature, and pain. These sensory abnormalities are often symmetrical and may follow the same distribution as muscle weakness.Â
In some cases of GBS, cranial nerves can be affected, leading to various cranial nerve deficits. For example, patients may experience facial weakness or paralysis (facial nerve palsy), difficulty swallowing or speaking, diplopia, or other cranial nerve-related symptoms. GBS can also impact the autonomic nervous system, leading to autonomic dysfunction.
This may manifest as changes in blood pressure, heart rate, sweating, and other involuntary bodily functions. The weakness and paralysis in GBS typically follow a symmetrical pattern, affecting both sides of the body similarly. Over time, as the nerves are affected, muscle wasting or atrophy may be observed in the affected limbs.Â
Differential DiagnosesÂ
Acute Intermittent Porphyria
Tick Paralysis
Currently, two standard treatment options are considered for Guillain-Barre Syndrome (GBS): intravenous immunoglobulin (IVIG) and plasma exchange. Although the exact mechanism of IVIG’s immune-modulating action remains to be fully understood, both IVIG and plasma exchange have been shown to be equally effective in managing GBS.
Plasma exchange involves five sessions of exchanging a volume of plasma. Treatment with either IVIG or plasma exchange within four weeks of symptom onset has demonstrated positive effects, with stronger benefits seen when treatment is initiated within two weeks.
Interestingly, corticosteroids, such as oral prednisone and intravenous methylprednisolone, have not shown significant benefits compared to placebo or when combined with IVIG and plasma exchange. Despite this, the overall treatment has been found to shorten the recovery duration of GBS. In a study, treated patients achieved independent ambulation 32 days faster than untreated patients.
This immune response leads to inflammation and damage to the myelin sheath. As a result, nerve signals are disrupted, leading to weakness, numbness, and paralysis. There are several subtypes of Guillain-Barre Syndrome, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which is the most common type, as well as acute motor axonal neuropathy (AMAN) and Miller Fisher syndrome.
Most people with Guillain-Barre Syndrome experience a gradual recovery over weeks or months, although some individuals may have lingering weakness or other long-term effects. Rehabilitation is often necessary to help patients regain their strength and functionality.
The annual incidence of GBS is estimated to be around 0.6 to 4 cases per 100,000 individuals. Incidence rates may vary across different populations and geographic regions. GBS can affect individuals of all ages, but it is more common in adults and older individuals. The peak age of onset is between 30 and 50 years old. Additionally, GBS appears to affect males slightly more often than females. In some regions, GBS has been observed to have seasonal patterns, with higher incidence rates reported during certain times of the year.
The reason for this seasonal variation is not entirely understood but could be linked to the prevalence of infections that trigger the condition. Occasionally, outbreaks of GBS have been reported in certain regions or after specific infections, such as the Zika virus outbreak in 2015-2016, which was associated with an increase in GBS cases in affected areas.
A small but increased risk of GBS is associated with some influenza vaccines, particularly the 1976 swine flu vaccine. However, the overall risk is extremely low, and the benefits of vaccination in preventing influenza far outweigh this risk. The incidence of GBS can vary between countries and regions. Some studies have suggested that it might be more common in developed countries compared to developing countries, but differences may also influence this observation in healthcare access and reporting systems.
GBS is often triggered by preceding infections, typically bacterial or viral. Molecular mimicry is one of the proposed mechanisms for GBS development. Infections, particularly those caused by Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and Zika virus, can produce antigens that closely resemble the structure of the peripheral nerves’ myelin sheath or nerve fibers. While trying to fight the infection, the immune system can mistakenly attack these similar antigens on the nerves, leading to an autoimmune response.
The immune system, primarily involving T-cells and B-cells, becomes activated and attacks the peripheral nerves. This immune response leads to inflammation and damage to the myelin sheath—the protective covering of the nerves—and sometimes to the axons (nerve fibers). As the myelin sheath is damaged, nerve conduction is disrupted, resulting in the characteristic symptoms of GBS, such as weakness, numbness, and paralysis.
The blood-nerve barrier is a protective barrier that separates the blood vessels from the peripheral nerves. In GBS, the immune response can cause the breakdown of this barrier, leading to an influx of immune cells and proteins into the nerve tissues. This further promotes inflammation and nerve damage. The autoimmune response and activation of the immune system lead to inflammation in and around the affected nerves.
Inflammatory cells, cytokines, and other immune mediators contribute to tissue damage and edema, further impairing nerve function. In some cases, the immune response can directly damage the axons of the nerves. This type of nerve damage can lead to more severe and prolonged weakness and slower recovery compared to cases with primary demyelination.
Guillain-Barre Syndrome (GBS) is an autoimmune disorder whose etiology involves a complex interplay of factors. The primary trigger for GBS is often a preceding infection, most commonly caused by bacteria or viruses. Infections such as Campylobacter jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Zika virus have been implicated as potential triggers for GBS. During these infections, the immune system responds to combat the invading pathogens.
However, in some individuals, the immune system’s response becomes misdirected, leading to an attack on the body’s peripheral nerves. Infections can produce antigens that closely resemble components of the myelin sheath or nerve fibers of peripheral nerves. These similar antigens can confuse the immune system, leading it to attack the infection and the nerve tissues, resulting in an autoimmune response.
While the etiology of GBS is not entirely understood, ongoing research continues to shed light on the underlying mechanisms and contributing factors. Understanding the complex interactions between infections, the immune system, and peripheral nerves is crucial for developing more effective treatments and interventions for this rare and potentially severe neurological disorder.
Following the acute phase of Guillain-Barre Syndrome (GBS), most patients experience favorable outcomes, with over 80% achieving independent ambulation within six months.
The mortality rate during the acute stage of the illness remains below 5%. However, a smaller subset, accounting for less than 20% of cases, may still face substantial disabilities despite receiving the standard of care for GBS.
Clinical History
Before the onset of GBS symptoms, there is often a prodromal phase characterized by a recent history of infection or illness. Commonly, GBS is triggered by bacterial or viral infections, such as respiratory or gastrointestinal infections, including Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, and others. The prodromal phase can last for a few days to a few weeks.
The hallmark symptoms of GBS usually start with weakness and tingling sensations in the extremities, most commonly in the feet and hands. These symptoms typically progress rapidly and symmetrically, spreading to the arms and legs. The onset of symptoms is usually sudden and may occur within a few hours to a few days after the prodromal phase.
After the initial progression of symptoms, there is a plateau phase where the weakness and sensory deficits stabilize and reach their maximum severity. This phase can last for several days to a few weeks. During this period, patients may experience significant muscle weakness and difficulty walking and may even have difficulty performing basic activities of daily living.
Physical ExaminationÂ
One of the primary features of GBS is symmetrical muscle weakness, which typically starts in the extremities and progresses upwards. The weakness may be more pronounced in the legs than in the arms. Patients may have difficulty lifting their arms or legs against gravity, and their muscle strength may be significantly reduced. Deep tendon reflexes, such as the knee jerk reflex (patellar reflex) or ankle reflex (Achilles reflex), are low during the examination.
In GBS, these reflexes are often diminished or absent due to nerve damage affecting the communication between the muscles and the spinal cord. GBS can cause sensory disturbances, such as numbness, tingling, reduced sensitivity to touch, temperature, and pain. These sensory abnormalities are often symmetrical and may follow the same distribution as muscle weakness.Â
In some cases of GBS, cranial nerves can be affected, leading to various cranial nerve deficits. For example, patients may experience facial weakness or paralysis (facial nerve palsy), difficulty swallowing or speaking, diplopia, or other cranial nerve-related symptoms. GBS can also impact the autonomic nervous system, leading to autonomic dysfunction.
This may manifest as changes in blood pressure, heart rate, sweating, and other involuntary bodily functions. The weakness and paralysis in GBS typically follow a symmetrical pattern, affecting both sides of the body similarly. Over time, as the nerves are affected, muscle wasting or atrophy may be observed in the affected limbs.Â
Differential DiagnosesÂ
Acute Intermittent Porphyria
Tick Paralysis
Currently, two standard treatment options are considered for Guillain-Barre Syndrome (GBS): intravenous immunoglobulin (IVIG) and plasma exchange. Although the exact mechanism of IVIG’s immune-modulating action remains to be fully understood, both IVIG and plasma exchange have been shown to be equally effective in managing GBS.
Plasma exchange involves five sessions of exchanging a volume of plasma. Treatment with either IVIG or plasma exchange within four weeks of symptom onset has demonstrated positive effects, with stronger benefits seen when treatment is initiated within two weeks.
Interestingly, corticosteroids, such as oral prednisone and intravenous methylprednisolone, have not shown significant benefits compared to placebo or when combined with IVIG and plasma exchange. Despite this, the overall treatment has been found to shorten the recovery duration of GBS. In a study, treated patients achieved independent ambulation 32 days faster than untreated patients.
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
